PriceTargets.com logo

Satellos Bioscience - MSLE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 220.28%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.62 As of 06/5/2026 05:00 PM ET
▼ -0.39 (-6.49%)

This chart shows the closing price for MSLE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Satellos Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MSLE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MSLE

Analyst Price Target is $18.00
▲ +220.28% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Satellos Bioscience in the last 3 months. The average price target is $18.00, with a high forecast of $23.00 and a low forecast of $11.00. The average price target represents a 220.28% upside from the last price of $5.62.

This chart shows the closing price for MSLE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Satellos Bioscience. This rating has held steady since April 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/8/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/7/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/21/2026Canaccord Genuity GroupUpgradeModerate Buy
5/18/2026HC WainwrightReiterated RatingBuy ➝ Buy$11.00
5/11/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/28/2026GuggenheimInitiated CoverageBuy$23.00
4/6/2026Leerink PartnersInitiated CoverageOutperform$20.00
3/30/2026HC WainwrightBoost TargetBuy ➝ Buy$11.00
3/11/2026Cantor FitzgeraldInitiated CoverageOverweight
2/11/2026Weiss RatingsInitiated CoverageSell (D-)
2/10/2026Zacks ResearchUpgradeHold
(Data available from 6/6/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/7/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2026

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Satellos Bioscience

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.
Read More

Today's Range

Now: $5.62
Low: $5.62
High: $6.18

50 Day Range

MA: $6.95
Low: $5.59
High: $8.70

52 Week Range

Now: $5.62
Low: $4.53
High: $13.39

Volume

36,868 shs

Average Volume

32,900 shs

Market Capitalization

$117.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Satellos Bioscience?

The following sell-side analysts have issued stock ratings on Satellos Bioscience in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Guggenheim, HC Wainwright, Leerink Partners, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for MSLE.

What is the current price target for Satellos Bioscience?

0 Wall Street analysts have set twelve-month price targets for Satellos Bioscience in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 220.3%. Guggenheim has the highest price target set, predicting MSLE will reach $23.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Satellos Bioscience in the next year.
View the latest price targets for MSLE.

What is the current consensus analyst rating for Satellos Bioscience?

Satellos Bioscience currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MSLE.

How do I contact Satellos Bioscience's investor relations team?

Satellos Bioscience's physical mailing address is 65 FRONT STREET EAST, SUITE 201, TORONTO, A6, M5E 1B5. The company's listed phone number is (905) 336-6128 and its investor relations email address is [email protected]. The official website for Satellos Bioscience is satellos.com. Learn More about contacing Satellos Bioscience investor relations.